Alan Schecter, MD
Pulmonary Disease · Great Neck, NYNPI 1407895774
Payments from drug & device makers
Across 857 payments — averaging $120.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$64K
- Mylan Specialty L.p.$12K
- AstraZeneca$8K
- Sunovion Pharmaceuticals Inc.$7K
- Genentech USA, Inc.$3K
- Boehringer Ingelheim$2K
- plus $7K from 31 others
What the payments were for
- Consulting fees$1,8402%
- Speaking & faculty fees$77,67075%
- Travel & lodging$4,5934%
- Food & beverage$19,00118%
- Education$1240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 240 | $63,991 |
| Mylan Specialty L.p. | 65 | $12,130 |
| AstraZeneca(2 entities) | 95 | $7,501 |
| Sunovion Pharmaceuticals Inc. | 54 | $7,464 |
| Genentech USA, Inc. | 29 | $3,400 |
| Boehringer Ingelheim | 93 | $2,228 |
| Actelion Pharmaceuticals US, Inc. | 45 | $1,004 |
| Novartis | 32 | $671 |
| Regeneron Healthcare Solutions, Inc. | 25 | $623 |
| Sanofi | 19 | $527 |
| Insmed, Inc. | 15 | $449 |
| Advanced Respiratory, Inc | 14 | $305 |
| Johnson & Johnson | 17 | $302 |
| Electromed, Inc. | 16 | $288 |
| Philips North America LLC | 9 | $286 |
| Grifols USA, LLC | 11 | $251 |
| Baxter Healthcare | 9 | $234 |
| Verona Pharma, Inc. | 8 | $208 |
| Viatris Specialty LLC | 10 | $193 |
| Mallinckrodt Hospital Products Inc. | 6 | $179 |
| Pfizer | 9 | $158 |
| Bayer | 6 | $131 |
| Olympus America Inc. | 1 | $125 |
| Amgen | 4 | $94 |
| Teva Pharmaceuticals USA, Inc. | 5 | $82 |
| Inspire Medical Systems, Inc. | 3 | $63 |
| Shire North American Group Inc | 3 | $56 |
| Merck | 2 | $51 |
| Shionogi Inc | 2 | $42 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Circassia Inc. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| United Therapeutics Corporation | 1 | $25 |
| Melinta Therapeutics, LLC | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Gilead | 1 | $13 |
| Cumberland Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$25,825
- NUCALA$21,282
- Yupelri$11,039
- ANORO$8,704
- LONHALA MAGNAIR$6,762
- BREZTRI AEROSPHERE$5,498
- ANORO ELLIPTA$3,921
- XOLAIR$2,752
- DUPIXENT$128
- OFEV$125
- Arikayce$114
- inCourage$113
How this compares
$103,228 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 30 | $383,508 |
| UptraviSelexipag | 12 | $279,739 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 209 | $193,473 |
| Dupixent PenDupilumab | 44 | $190,965 |
| Dupixent SyringeDupilumab | 30 | $119,452 |
| Breo ElliptaFluticasone/Vilanterol | 167 | $109,228 |
| XolairOmalizumab | 34 | $84,945 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 81 | $77,084 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 68 | $42,794 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 104 | $18,594 |
| Spiriva RespimatTiotropium Bromide | 17 | $18,404 |
| SymbicortBudesonide/Formoterol Fumarate | 42 | $16,769 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 20 | $12,913 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $9,964 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 262 | $9,665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $2,228 | $411,87762 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta | $63,991 | $351,140459 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $1,004 | $279,73912 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $7,501 | $106,766143 claims |
| MerckDulera | $51 | $7,04716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Great Neck
- Jeffrey WolfGreat Neck$892K
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.